$SLS and $MBRX, two AML stocks with imminent catalysts
$SLS has the stronger financial position and the larger current valuation with a market cap of about $1.13B. They are in great shape as they approach the key REGAL Phase 3 readout, where 78 of the required 80 death events had occurred as of May 11, 2026. This is notable as they were expecting the final event to occur many months ago. Their readout could be within the next couple of months.
$MBRX is the smaller, higher-risk/higher-upside stock. Their market cap is 1/100th of that of $SLS sitting at around $11m at the moment. They announced yesterday that they hit the enrollment target for the interim readout of their pivotal trial with early blinded data showing a preliminary 40% CRc rate in the first 45 subjects while the historical rate is around $17%-18%. Their readout is by the end of June, likely earlier.
I hope they are both successful, as they do not compete with each other but they fit together. $MBRX gets patients into remission while $SLS helps keep them there.
Not financial advice and keep in mind that AML is very hard to treat!
Sources